Inhibición de la angiogénesis: - page 48

Future with Nintedanib
•
Combination with Immunotherapy
: strong
preclinical evidence
•
Combination with EGFR-TKI
•
Combinations with CT to improve tolerability
:
–
Nab-paclitaxel
–
Docetaxel weekly
•
Investigation of Potential Biomarkers
:
LUME-
BioNIS Study
1...,38,39,40,41,42,43,44,45,46,47 49,50,51,52,53,54,55,56,57
Powered by FlippingBook